Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
8.77
+0.22 (2.57%)
At close: Aug 4, 2026, 4:00 PM EDT
8.60
-0.17 (-1.94%)
After-hours: Aug 4, 2026, 5:11 PM EDT

Atara Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
23.14120.77128.948.5763.5720.34
Revenue Growth
-88.41%-6.33%1404.02%-86.52%212.55%-
Gross Profit
22.2499.56107.93-0.3163.5720.34
Operating Income
-6.3135.86-83.44-276.01-280.51-340.46
Net Income
-9.4732.69-85.4-276.13-228.3-340.14
Earnings Per Share
-0.782.57-11.41-65.19-56.00-90.75
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
8.368.4842.551.73242.82371.07
Total Debt
9.089.3529.9145.6958.0625.52
Net Cash (Debt)
-0.72-0.8712.586.03184.76345.55
Net Cash Growth
--108.59%-96.73%-46.53%-29.13%
Net Cash Per Share
-0.05-0.071.681.4245.2992.23

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-25.88-50.94-68.72-192.98-270.43-220.52
Capital Expenditures
---0.25-1.22-4.19-10.58
Free Cash Flow
-25.88-50.94-68.96-194.2-274.62-231.1
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
96.12%82.44%83.71%-3.65%100.00%100.00%
Operating Margin
-27.27%29.69%-64.71%-3219.48%-441.25%-1673.85%
Pretax Margin
-40.78%27.09%-66.24%-3220.70%-359.10%-1672.05%
Profit Margin
-40.91%27.07%-66.23%-3220.88%-359.12%-1672.28%
FCF Margin
-111.82%-42.18%-53.48%-2265.25%-431.98%-1136.19%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-7.04----
Forward PE
-19.660.30---
PS Ratio
3.411.100.606.374.9571.03